THCV (Tetrahydrocannabivarin): What It Is and What Research Shows

Overview

THCV (tetrahydrocannabivarin, also written Δ9-THCV) is a plant cannabinoid that looks like THC in structure but is a different compound. A 2025 review argues that THCV is usually and incorrectly treated as an intoxicating analogue of THC, and that it has distinct pharmacology. [1] NIDA, however, lists THCV among compounds with limited research on health effects. [2] Both statements can be true: the compound acts differently from THC in laboratory work, but human data are thin. For the main compound, see THC. This guide uses plain evidence labels: promising but limited, mixed, insufficient evidence, preclinical (cells/animals only) and marketing claim. "Proper evidence not found" means we looked and found nothing usable.

How it acts in the body

• At the CB1 receptor. Reviews describe THCV as a potent blocker (antagonist) of cannabinoid agonists in CB1-expressing tissues in the laboratory, and as a CB2 receptor partial agonist. [3] A 2015 systematic review adds that although THCV binds CB1 strongly in vitro, it only occasionally produces effects in animals from CB1 blocking. [4] Label: preclinical (cells/animals only) for most of this.
• Not the same as THC. In a 2024 mouse study, THCV did not alter the discriminative stimulus effects of delta-9 THC. [5] This is animal work and does not prove how people feel after any product.
• Different profile. The 2025 review says THCV has distinct pharmacological activity and effects from THC at the doses reported in the literature. [1]

Where it comes from

THCV is a phytocannabinoid, meaning a cannabinoid made by the plant. [1] Proper evidence not found, in the sources we read, for typical amounts in plants or products; composition varies, and only batch-specific lab reports can show it. See how to read a cannabis COA.

What research shows in people

• Type 2 diabetes pilot trial (2016). In a randomized, double-blind, placebo-controlled pilot study, 62 people with type 2 diabetes who were not on insulin were assigned to five groups for 13 weeks. [6] Compared with placebo, THCV significantly decreased fasting plasma glucose, while HDL cholesterol (the main target) was unaffected. [6] None of the combination treatments with CBD had a significant effect, and THCV was well tolerated. [6] Label: promising but limited. It is one small pilot study, in one condition, and does not support using any product for diabetes.
• Weight and appetite. A 2025 review says preliminary human trials suggest THCV may modulate appetite and blood sugar, but larger studies are needed. [7] The popular nickname "diet weed" is a marketing term; the 2025 THCV review notes it arose despite few human studies. [1] Label: insufficient evidence for weight loss.
• Mental health. A 2025 systematic review of minor cannabinoids in psychiatric disorders included 22 preclinical studies and only one clinical study overall, with moderate to high risk of bias in several articles. [8] Proper evidence not found for THCV treating a psychiatric condition in people.
• Brain protection. A 2020 review found THCV showed promise in animal models of seizures and of Huntington's and Parkinson's disease. [9] Label: preclinical (cells/animals only). Do not apply this to people.

Risks and safety

The diabetes trial reported THCV as well tolerated in that study. [6] That is not a full safety profile: Proper evidence not found for long-term safety, drug interactions or use in children, pregnancy or breastfeeding. Anyone taking diabetes medicines should talk with a prescriber before any new product, because THCV was studied for its effect on blood sugar. [6] See cannabis and medicine interactions and pregnancy and breastfeeding.

Quality and labeling

THCV is sold in some consumer products, sometimes alongside other cannabinoids. Claims about weight, focus or energy are marketing claims unless a human trial is cited. See cannabinoid products marketed for energy or focus.

Legal status

Not verified. We did not read a regulator page that sets out THCV's legal category, and some laws treat THC-like compounds as a group. See cannabis laws by country. This is not legal advice.

Related guides

Minor cannabinoids at a glance and Cannabinoids explained.